Shareholders of vaccine and antibody therapy specialist Emergent BioSolutions (NYSE:EBS) were feeling a bit queasy on Friday afternoon. That day, the company's stock fell by almost 4.9% after the release of the latest quarterly earnings.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,